| Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, ... Leukemia 33 (1), 64-74, 2019 | 265 | 2019 |
| Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism C Krupka, P Kufer, R Kischel, G Zugmaier, FS Lichtenegger, T Köhnke, ... Leukemia 30 (2), 484-491, 2016 | 265 | 2016 |
| CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 C Krupka, P Kufer, R Kischel, G Zugmaier, J Bögeholz, T Köhnke, ... Blood, The Journal of the American Society of Hematology 123 (3), 356-365, 2014 | 227 | 2014 |
| Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab T Köhnke, C Krupka, J Tischer, T Knösel, M Subklewe Journal of hematology & oncology 8, 1-5, 2015 | 179 | 2015 |
| Recent developments in immunotherapy of acute myeloid leukemia FS Lichtenegger, C Krupka, S Haubner, T Köhnke, M Subklewe Journal of hematology & oncology 10, 1-20, 2017 | 171 | 2017 |
| Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia M Rothenberg-Thurley, S Amler, D Goerlich, T Köhnke, NP Konstandin, ... Leukemia, 1-27, 2017 | 147 | 2017 |
| Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia H Zhang, Y Nakauchi, T Köhnke, M Stafford, D Bottomly, R Thomas, ... Nature cancer 1 (8), 826-839, 2020 | 131 | 2020 |
| Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse M Hubmann, T Köhnke, E Hoster, S Schneider, A Dufour, E Zellmeier, ... Haematologica 99 (8), 1317, 2014 | 92 | 2014 |
| Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis KH Weylandt, A Nadolny, L Kahlke, T Köhnke, C Schmöcker, J Wang, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1782 (11 …, 2008 | 84 | 2008 |
| Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse T Köhnke, D Sauter, K Ringel, E Hoster, RP Laubender, M Hubmann, ... Leukemia 29 (2), 377-386, 2015 | 79 | 2015 |
| Single-cell mutational profiling enhances the clinical evaluation of AML MRD A Ediriwickrema, A Aleshin, JG Reiter, MR Corces, T Köhnke, M Stafford, ... Blood advances 4 (5), 943-952, 2020 | 77 | 2020 |
| Immunotherapy for acute myeloid leukemia FS Lichtenegger, C Krupka, T Köhnke, M Subklewe Seminars in hematology 52 (3), 207-214, 2015 | 74 | 2015 |
| Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings J Tischer, N Engel, S Fritsch, D Prevalsek, M Hubmann, C Schulz, ... Annals of hematology 94, 1677-1688, 2015 | 73 | 2015 |
| Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD 200 T Köhnke, VK Wittmann, VL Bücklein, F Lichtenegger, Z Pasalic, ... British journal of haematology 179 (3), 480-487, 2017 | 72 | 2017 |
| Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC) D Di Gioia, V Heinemann, D Nagel, M Untch, S Kahlert, I Bauerfeind, ... Tumor Biology 32, 777-785, 2011 | 53 | 2011 |
| Targeting CD157 in AML using a novel, Fc-engineered antibody construct C Krupka, FS Lichtenegger, T Köhnke, J Bögeholz, V Bücklein, M Roiss, ... Oncotarget 8 (22), 35707, 2017 | 37 | 2017 |
| Clonal hematopoiesis: from mechanisms to clinical intervention T Köhnke, R Majeti Cancer discovery 11 (12), 2987-2997, 2021 | 36 | 2021 |
| Acetylsalicylic Acid Reduces the Severity of Dextran Sodium Sulfate‐Induced Colitis and Increases the Formation of Anti‐Inflammatory Lipid Mediators T Köhnke, B Gomolka, S Bilal, X Zhou, Y Sun, M Rothe, DC Baumgart, ... BioMed research international 2013 (1), 748160, 2013 | 34 | 2013 |
| Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial FS Lichtenegger, FM Schnorfeil, M Rothe, K Deiser, T Altmann, ... Clinical & Translational Immunology 9 (3), e1117, 2020 | 33 | 2020 |
| Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2 R Dutta, TY Zhang, T Köhnke, D Thomas, M Linde, E Gars, M Stafford, ... The Journal of clinical investigation 130 (4), 1843-1849, 2020 | 27 | 2020 |
